Drug therapies based on engineered proteins introduced new paradigms in the treatment of diseases in the late 20th and early 21st centuries. Today, engineered proteins are among the best-selling pharmaceuticals worldwide and are proving to be competitors, and in some cases significantly superior, to the drugs based on small chemical molecules. In the article, using documentary methods for analyzing published scientific data from preclinical and clinical trials of engineered proteins for therapeutic purposes, modern designs of therapeutic engineered proteins are considered in terms of increased affinity, specificity, stability, cell permeability and pharmacokinetics, as well as reduced doses in connection with possible unwanted immunogenicity. Different strategies for the design of engineered proteins, representing various structural modifications, are considered:
1. Site-specific mutagenesis;
2. Antibody–drug conjugates;
3. PEGylation;
4. Glycosylation;
5. Fc synthesis;
6. Synthesis of other proteins;
7. Lipidation;
8. Attachment of non-PEG polymers;
9. Supercharging;
10. Computational design.
Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21-39. doi: 10.1038/nrd2399.
Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4(4):298-306. doi: 10.1038/nrd1695.
Hoyt E, Cal P, Bruno L et al. Contemporary approaches to site-selective protein modification. Nat Rev Chem. 2019;3:147-171. doi: 10.17863/CAM.36322
Radeva-Ilieva M. A review of cancer immunotherapy: immune checkpoint inhibitors. Annual for Hospital Pharmacy. 2023;9(1):36-43. doi: 10.14748/ahp.v9i1.9187;
Tsenov S, Radeva-Ilieva M, Grigorov E. Present and future of targeted therapies in oncology. Bulgarian Journal of Public Health. 2023;15(3):5-15. doi: 10.5281/zenodo.10157603
Kontos S, Hubbell JA. Drug development: longer-lived proteins. Chem Soc Rev. 2012;7;41(7):2686-95. doi: 10.1039/c2cs15289d. Epub 2012 Feb 6.
Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214-21. doi: 10.1038/nrd1033.
Marshall Sh, Lazar G, Chirino A, Desjarlais J. Rational design and engineering of therapeutic proteins. Drug Discov Today. 2003;1;8(5):212-21. doi: 10.1016/s1359-6446(03)02610-2.
Varewijck AJ, Janssen JA. Insulin and its analogues and their affinities for the IGF1 receptor. Endocrine-related cancer. 2012;19:F63-75. doi: 10.1530/ERC-12-0026
Xia X, Longo LM, Blaber M. Mutation choice to eliminate buried free cysteines in protein therapeutics. J Pharm Sci. 2015;104(2):566-76. doi: 10.1002/jps.24188.
Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front Immunol. 2019;10:1296. doi: 10.3389/fimmu.2019.01296.
Loo YM, McTamney, Arends R et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans. Sci Transl Med. 2022;25:eabl8124. doi: 10.1126/scitranslmed.abl8124
Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014;53(15):3796-827. doi: 10.1002/anie.201307628.
Guo J, Kumar S, Chipley M et al. Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation. Bioconjug Chem. 2016;27(3):604-15. doi: 10.1021/acs.bioconjchem.5b00603
Axup J, Bajjuri K, Ritland M et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci USA. 2012;109(40):16101-6. doi: 10.1073/pnas.1211023109.
Park A, Honey DM, Hou L et al. Carbohydrate-mediated polyethylene glycol conjugation of TSH improves its pharmacological properties. Endocrinology. 2013;154(3):1373-83. doi: 10.1210/en.2012-2010.
Lundberg P, Lee BF, Van den Berg SA et al. Poly[(ethylene oxide)-co-(methylene ethylene oxide)]: A hydrolytically-degradable poly(ethylene oxide) platform. ACS Macro Lett. 2012;1(11):1240-1243. doi: 10.1021/mz300477t
Mohler KM, Torrance DS, Smith CA et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151(3):1548-61. PMID: 8393046
Shiga Y, Murata D, Sugimoto A et al. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin. Mol Pharm. 2017;14(9):3025-3035. doi: 10.1021/acs.molpharmaceut.7b00221
Liu Z, Chen X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev. 2016;45(5):1432-56. doi: 10.1039/c5cs00158g
Einsele H, Borghaei H, Orlowski R et al. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126(14):3192-3201. doi: 10.1002/cncr.32909
Ballew N, Gerngross T. Production of therapeutic proteins in fungal hosts. Expert Opin Biol Ther. 2004;4(5):623-6. doi: 10.1517/14712598.4.5.623
Dammen-Brower K. Epler P, Zhu S et al. Strategies for Glycoengineering Therapeutic Proteins. Front Chem. 2022;13:10:863118. doi: 10.3389/fchem.2022.863118.
Menacho-Melgar R, Decker JS, Hennigan JN, Lynch MD. A review of lipidation in the development of advanced protein and peptide therapeutics. J Control Release. 2019;295:1-12. doi: 10.1016/j.jconrel.2018.12.032
Venanzi M, Savioli M, Cimino R et al. A spectroscopic and molecular dynamics study on the aggregation process of a long-acting lipidated therapeutic peptide: the case of semaglutide. Soft Matter. 2020;16(44):10122-10131. doi: 10.1039/d0sm01011a
Anfinsen CB. Principles that govern the folding of protein chains. Science. 1973;20;181(4096):223-30. doi: 10.1126/science.181.4096.223
Vivona S, Gardy JL, Ramachandran S. Computer-aided biotechnology: from immuno-informatics to reverse vaccinology. Trends Biotechnol. 2008;26(4):190-200. doi: 10.1016/j.tibtech.2007.12.006
Silva D-A, Yu S, Ulge U et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019;565(7738):186-191. doi: 10.1038/s41586-018-0830-7
Ma C, Malessa A, Boersma A et al. Supercharged Proteins and Polypeptides. Adv Mater. 2020;32:e1905309. doi: 10.1002/adma.201905309
Cronican J, Beier K, Davis T et al. A Class of Human Proteins that Deliver Functional Proteins into Mammalian Cells In Vitro and In Vivo. Chem Biol. 2011;18:833-838. doi: 10.1016/j.chembiol.2011.07.003
Brodin J, Sprangers H, McMillan JR, Mirkin CA. DNA-Mediated Cellular Delivery of Functional Enzymes. J Am Chem Soc. 2015 Dec 2;137(47):14838-41. doi: 10.1021/jacs.5b09711
Samanta D, Ebrahimi S, Kusmierz C et al. Protein Spherical Nucleic Acids for Live-Cell Chemical Analysis. J Am Chem Soc. 2020;142(31):13350-13355. doi: 10.1021/jacs.0c06866
McMullen P, Fang L, Qiao Q et al. Impacts of a Zwitterionic Peptide on its Fusion Protein. Bioconjug Chem. 2022;17;33(8):1485-1493. doi: 10.1021/acs.bioconjchem.2c00176
Wals K, Ovaa H, Klauser P et al. Unnatural amino acid incorporation in E. coli: current and future applications in the design of therapeutic proteins. Front Chem. 2014:2:15. doi: 10.3389/fchem.2014.00015.
Li Q, Chen Q, Klauser PC et al. Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics. Cell. 2020;182(1):85-97.e16. doi: 10.1016/j.cell.2020.05.028.
Email this article (Login required) 
